View in EDS HTML Full Text PDF Full Text

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Saved in:
Bibliographic Details
Title: Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.
Authors: Watanabe, Makoto1,2,3,4 (AUTHOR), Ieguchi, Katsuaki1,2 (AUTHOR), Shimizu, Takashi1,2,3 (AUTHOR), Ohkuma, Ryotaro4,5,6 (AUTHOR), Suzuki, Risako3,4,5 (AUTHOR), Mura, Emiko5,6 (AUTHOR), Iriguchi, Nana1,5 (AUTHOR), Ishiguro, Tomoyuki2,5 (AUTHOR), Hirasawa, Yuya3,5 (AUTHOR), Ikeda, Go4,5 (AUTHOR), Shimokawa, Masahiro5 (AUTHOR), Ariizumi, Hirotsugu5,6 (AUTHOR), Yoshimura, Kiyoshi2,5 (AUTHOR), Horiike, Atsushi5 (AUTHOR), Tsunoda, Takuya5,6 (AUTHOR), Tsuji, Mayumi4 (AUTHOR), Kobayashi, Shinichi2 (AUTHOR), Oguchi, Tatsunori3,4 (AUTHOR), Kiuchi, Yuji3 (AUTHOR), Wada, Satoshi1,2,3,5 (AUTHOR) st-wada@med.showa-u.ac.jp
Source: Cancers. Jul2025, Vol. 17 Issue 14, p2384. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20726694
DOI:10.3390/cancers17142384